Failure to respond at endpoint (6‐12 weeks) · patients with induction of remission in ulcerative colitis
Etrolizumab showed no clear difference in failure to respond at week 10 compared with placebo (moderate certainty).
1 finding from 1 review
Failure to induce endoscopic remission · patients with induction of remission in ulcerative colitis
Etrolizumab showed no clear difference in failure to enter endoscopic remission at week 6 compared with placebo (moderate certainty).
2 findings from 1 review
Adverse events · patients with induction of remission in ulcerative colitis
Etrolizumab probably leads to lower adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with induction of remission in ulcerative colitis
Etrolizumab showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Remission · Participants with Crohn's disease in remission
Budesonide 6 mg showed no clear difference in continued remission at 3 months compared with placebo (low certainty).
3 findings from 1 review
RR 1.25 [1, 1.58]
6 studies · 540 participants
Low
RR 1.15 [0.95, 1.39]
5 studies · 420 participants
Moderate
RR 1.13 [0.94, 1.35]
5 studies · 420 participants
Moderate
Remission · Participants with Crohn's disease in remission
Budesonide 9 mg showed no clear difference in continued remission at 12 months compared with budesonide 6 mg (moderate certainty).
1 finding from 1 review
Remission · Participants with Crohn's disease in remission
Budesonide 9 mg showed no clear difference in continued remission at 12 months compared with prednisolone 40 mg (low certainty).
1 finding from 1 review
Remission · Participants with Crohn's disease in remission
It is very uncertain whether budesonide 6 mg changes continued remission at 12 months compared with mesalamine 3 g (very low certainty).
1 finding from 1 review
Remission · Participants with Crohn's disease in remission
It is very uncertain whether budesonide 6‐9 mg changes continued remission at 12 months compared with azathioprine 2‐2.5 mg/kg (very low certainty).
1 finding from 1 review
Remission · Participants with Crohn's disease in remission
Budesonide 3 mg probably leads to higher continued remission at 3 months compared with placebo (moderate certainty).
3 findings from 1 review
RR 1.29 [1.01, 1.63]
4 studies · 263 participants
Moderate
RR 1.12 [0.83, 1.51]
3 studies · 180 participants
Moderate
RR 1.08 [0.87, 1.34]
5 studies · 442 participants
Moderate
Remission · Participants with Crohn's disease in remission
Budesonide 6 mg showed no clear difference in continued remission at 3 months compared with budesonide 3 mg (moderate certainty).
3 findings from 1 review
RR 1.07 [0.85, 1.34]
3 studies · 180 participants
Moderate
RR 1.12 [0.85, 1.47]
3 studies · 180 participants
Moderate
RR 1.18 [0.85, 1.65]
3 studies · 180 participants
Moderate
Failure to enter remission or possible remission at 16 weeks (Arora 1999) · adult patients with refractory Crohn's disease
Methotrexate showed no clear difference in failure to enter remission or possible remission at 16 weeks (Arora… compared with placebo (low certainty).
3 findings from 1 review
RR 3 [0.68, 13.31]
1 study · 33 participants
Low
RR 1.05 [0.79, 1.39]
1 study · 52 participants
Low
RR 0.75 [0.61, 0.93]
1 study · 141 participants
Moderate
Adverse events (Ardizzone 2003) · adult patients with refractory Crohn's disease
It is very uncertain whether methotrexate changes adverse events (Ardizzone 2003) compared with 6‐MP or azathioprine (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adult patients with refractory Crohn's disease
It is very uncertain whether methotrexate changes withdrawal due to adverse event (Oren 1997) compared with 6‐MP or azathioprine (very low certainty).
3 findings from 1 review
RR 1.23 [0.08, 18.74]
1 study · 58 participants
Very low
RR 2.13 [0.22, 21.17]
1 study · 31 participants
Very low
RR 1 [0.22, 4.52]
1 study · 54 participants
Very low
Failure to enter remission or possible remission at 16 weeks (Arora 1999) · adult patients with refractory Crohn's disease
It is very uncertain whether methotrexate changes failure to enter remission or possible remission at 30 weeks… compared with 5‐ASA (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adult patients with refractory Crohn's disease
It is very uncertain whether methotrexate changes withdrawal due to adverse event (Maté‐Jiménez 2000) compared with 5‐ASA (very low certainty).
1 finding from 1 review
Failure to enter remission at 14 weeks or 24 weeks (Feagan 2014) · adult patients with refractory Crohn's disease
Methotrexate + infliximab showed no clear difference in failure to enter remission at 14 weeks or 24 weeks (Feagan 2014) compared with infliximab alone (low certainty).
2 findings from 1 review
Adverse events (Schröder 2006) · adult patients with refractory Crohn's disease
It is very uncertain whether methotrexate + infliximab changes adverse events (Schröder 2006) compared with infliximab alone (very low certainty).
1 finding from 1 review
Serious adverse events (Schröder 2006) · adult patients with refractory Crohn's disease
It is very uncertain whether methotrexate + infliximab changes serious adverse events (Schröder 2006) compared with infliximab alone (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adult patients with refractory Crohn's disease
Methotrexate + infliximab showed no clear difference in withdrawals due to adverse event (Feagan 2014) compared with infliximab alone (low certainty).
1 finding from 1 review